18 reports

  • MARKET LANDSCAPE

The increased prevalence of the HIV-AIDS (acquired immune deficiency syndrome) has caused a Source: Technavio marked acceleration of the TB epidemic worldwide, particularly in Sub-Saharan Africa and Asian countries.

  • Pathology
  • Tuberculosis
  • World
  • Forecast
  • Sandoz Inc.

BD Source: Technavio Research BD Biosciences launched BD FACSPresto in 2014, an innovative near-patient CD## counter system, designed to test HIV/ AIDS patients in resource-limited settings outside the US.

  • Tuberculosis
  • World
  • Market Size
  • Alere Inc.
  • Roche Group

We are also advancing our assay development across a range of other infectious diseases, with tests under early stage design in HIV and Sepsis.

  • Tuberculosis
  • India
  • World
  • Epistem Holdings Plc
  • GlobalData's company

D' Orso said, describing the situation in which HIV infection leads to AIDS.

  • Cancer
  • HIV AIDS
  • Specialty Hospital
  • Tuberculosis
  • GlobalData's company
  • Jun 06, 2016: Speeding up drug discovery to fight tuberculosis

In fact, the number of worldwide deaths caused by tuberculosis has surpassed HIV/ AIDS, and there is greater sense of urgency than ever before to find effective drug cocktails to outsmart MTB.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.

In fact, the number of worldwide deaths caused by tuberculosis has surpassed HIV/ AIDS, and there is greater sense of urgency than ever before to find effective drug cocktails to outsmart MTB.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.
  • RODOS BIOTARGET GMBH
  • Peptides for Tuberculosis
  • DNA
  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Official Title
  • Official Title
  • Clinical Trial
  • Infectious Disease
  • Tuberculosis
  • World
  • TB Drug Development, Inc.

" The new CFAR builds on Einstein and Montefiore' s longstanding achievements in HIV and AIDS research and our shared commitment to social justice, " says Dr.

  • Cancer
  • Pharmaceutical
  • Tuberculosis
  • United States
  • GlobalData's company
  • Clinical Trial profile. 132 Trial Title
  • Clinical Trial profile. 50 Trial Title

Intermittent ## - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients with HIV and Pulmonary Tuberculosis Comparing Daily vs Intermittent Regimen of ATT in HIV with Pulmonary Tuberculosis GDCT## NCT##, T

  • Anti-Infective
  • Therapy
  • Tuberculosis
  • World
  • Product Initiative
  • Clinical Trial profile. 39 Trial Title
  • Clinical Trial profile. 76 Trial Title
  • Drug Discovery And Development
  • Tuberculosis
  • World
  • Product Initiative
  • TB Drug Development, Inc.
  • NOV 04, 2014: MBIO DIAGNOSTICS AWARDED CONTRACT FOR DIAGNOSTIC DEVELOPMENT WITH THE U.S. ARMY

Specifically, malaria, HIV/ AIDS, enteric pathogens, influenza, hemorrhagic fever viruses, and arthropod-borne diseases are among the most important of the militarily-relevant infectious agents.

  • Diagnostics
  • Tuberculosis
  • United States
  • Company
  • MBio Diagnostics, Inc.
  • TUBERCULOSIS - PIPELINE BY RECCE LTD, H2 2017
  • Indication Name
  • Research And Development
  • Tuberculosis
  • World
  • Product Initiative
  • TB Drug Development, Inc.
  • Immunitor, Inc. - Dormant Developmental Projects,2015
  • Immunitor, Inc. - Drug Profiles
  • Pathology
  • Tuberculosis
  • World
  • Product Initiative
  • Immunitor, Inc.
  • Globeimmune, Inc. - Pipeline by Indication, 2015
  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • GlobeImmune, Inc.

It interacts with the HIV envelope protein gp##, but not with the HIV cellular receptors.

  • Infectious Disease
  • Therapy
  • Tuberculosis
  • United States
  • Sanofi S.A.
  • SMALL MOLECULES FOR TUBERCULOSIS
  • NITD-349

The partnership is a milestone toward the development of faster TB drug regimens that treat all forms of TB, are easier for patients to complete, and can be used safely in patients with HIV/ AIDS.

  • Cancer
  • Targeted Therapy
  • Therapy
  • Tuberculosis
  • Novartis AG

The drug candidate is in Phase II stage of development for the treatment of ovarian or peritoneal cancer, neurofibromatoses type I and plexiform neurofibroma in Phase I/ II stage of development for the treatment of AIDS related Kaposi' s sarcoma and gliomas.

  • Cancer
  • Therapy
  • Tuberculosis
  • United States
  • AstraZeneca PLC